Methods of treatment that target anti-tau acetylation, such as inhibiting GAPDH nitrosylation, blocking p300/CBP, or activating Sirtuin1 have showed reduced brain atrophy, neuronal loss, and cognitive deficits in their model (139). This evidence concerns the gene MAPT and Brain atrophy.